CNS Viral Infections—What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches

Sun, Ming; Manson, Martijn L.; Guo, Tingjie; de Lange, Elizabeth C. M.

doi:10.1007/s40263-024-01082-3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Preprint1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 254 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?

Nau,

Seele,

Bodilsen

et al. 2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?

Nau,

Seele,

Bodilsen

et al. 2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approach

Sun,

Manson,

Märtson

et al. 2024

Preprint

View full text Add to dashboard Cite

Acyclovir is a primary treatment for central nervous system (CNS) infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV). However, patient outcomes remain suboptimal with high mortality and morbidity, following current dosing guidelines. Given the lack of alternative therapies, there is a pressing need to optimize acyclovir dosing, especially since initial regimens were developed in the 1980s with incomplete pharmacokinetic data in the CNS. This study aimed to evaluate both current and alternative acyclovir dosing regimens using a full Bayesian physiologically-based pharmacokinetic (PBPK) model tailored for viral encephalitis. We developed a CNS PBPK model to simulate acyclovir concentrations in plasma, brain extracellular fluid (ECF), and subarachnoid space (SAS). Drug efficacy was assessed using two pharmacokinetic targets, 50%fT>IC50and Cmin>IC50, with a safety threshold set at 25 mg/L in plasma. The standard dosing regimen (10 mg/kg TID) yielded sufficient acyclovir exposure in plasma, brain extracellular fluid (ECF), and subarachnoid space (SAS) compartments based on the 50%fT>IC50target. However, it did not consistently meet the Cmin>IC50target, indicating potential suboptimal exposure in these compartments when evaluated against this criterion. Notably, a higher probability of target attainment (PTA) was generally observed in the brain ECF and SAS compared to plasma. Increasing the dosing frequency to QID improved target attainment but exceeded the toxicity threshold at 20 mg/kg. Our findings suggest that a dosing regimen of 10 mg/kg or 15 mg/kg QID may offer a more effective and safer approach for managing CNS infections compared to the other tested alternative dosing regimens.

show abstract

CNS Viral Infections—What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches

Cited by 2 publications

References 254 publications

Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?

Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome?

Revisiting acyclovir dosing for viral encephalitis using a Bayesian PBPK modeling approach

Contact Info

Product

Resources

About